NCT02256553View on ClinicalTrials.gov

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Rhinitis, Allergic, Seasonal
Interventions
BIOLOGICAL

MK-3641 12 Amb a 1-U (short ragweed extract)

12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets

BIOLOGICAL

MK-7243 2800 BAU (Timothy grass extract)

2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets

DRUG

Rescue Medication

Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY

NCT02256553 - Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) | Biotech Hunter | Biotech Hunter